Briacell Therapeutics Corp · TSX:BCT

Briacell Therapeutics — Investor Presentation (February 2021)

15 slides from Briacell Therapeutics's investor presentation, February 2021

  1. Slide 1: BriaCell Therapeutics Corp. Investor Presentation February 2021

    The Future of Cancer Immunotherapy BriaCell Therapeutics Corp. BCT:TSXV; BCTXF:OTCQB Investor Presentation February 2021 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements BriaCell Therapeutics Corp. (“BriaCell”) Except for historical information, this presentation contains forward-looking statements, which reflect BriaCell’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and un

  3. Slide 3: BriaCell Corporate Highlights

    BriaCell Corporate Highlights  BriaCell Therapeutics Corp. (BCT:TSXV; BCTXF:OTC) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors including Bria-IMT™ for advanced breast cancer (the cause of ov

  4. Slide 4: BriaCell's Expert Drug Development & Financial Team

    BriaCell’s Expert Drug Development & Financial Team William V. Williams, MD, FACP, President & CEO, Director Jamieson Bondarenko, CFA, CMT, Chairman of the Board  Former VP, Exploratory Development, Incyte Corporation  Previously Principal and Managing Director of the Equity Capital Markets group

  5. Slide 5: BriaCell Pipeline

    BriaCell Pipeline Therapeutic Indication Preclinical Phase I Phase II Phase III Anticipated Milestones Bria-IMT™ combined Advanced Breast Cancer Phase I/II Further safety and efficacy with Incyte Compounds (3rd+ line) data through 2021 Bria-OTS™ Breast Cancer IND filing 2021 NICL1* Prostate Cancer I

  6. Slide 6: BriaCell's Patented Immunotherapy: Bria-IMT

    BriaCell’s Patented Immunotherapy: Bria-IMT™ Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that is believed by us to directly stimulate the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. Antigens Tumor Destruction CD8+

  7. Slide 7: Bria-IMT – Phase I/IIa Efficacy

    Bria-IMT™ – Phase I/IIa Efficacy Mechanism of Action & Proof-of-Concept  4 patients treated by Dr. Wiseman in 2004-2005 (original patients), including one remarkable responder  23 patients were dosed in 2017-2018 (phase I/IIa), all very heavily pre-treated (with chemotherapy).  Safety & Efficacy

  8. Slide 8: Bria-IMT in Combination with Immune Checkpoint Inhibitors

    Bria-IMT™ in Combination with Immune Checkpoint Inhibitors How Do Checkpoint Inhibitors Work? • PD-L1 molecules block immune cells from attacking cancer cells • Immune checkpoint inhibitors (such as pembrolizumab (KEYTRUDA®)) are designed to neutralize this immune suppression in cancer patients Why

  9. Slide 9: Bria-IMT + Immune Checkpoint Inhibitor Combination Study Data

    Bria-IMT™ + Immune Checkpoint Inhibitor Combination Study Data Phase I/IIa Combination Study  Patients were treated with the combination of Bria-IMT™ and anti-PD-1 antibody KEYTRUDA®.  We believe that an excellent safety and tolerability profile on the first 11 patients was observed.  All 11 pati

  10. Slide 10: Bria-IMT + Immune Checkpoint Inhibitor: Remarkable Responder

    Bria-IMT™ + Immune Checkpoint Inhibitor: Remarkable Responder Tumor behind the left eye causing proptosis completely resolves Six months Baseline On Treatment Scans Scans Complete resolution of orbital tumor in a heavily pre-treated patient with 2 HLA matches and a grade II tumor supports remarkable

  11. Slide 11: Bria-IMT in Grade I/II Tumors

    Bria-IMT™ in Grade I/II Tumors Breast Cancer Grade Correlates with Response Cell Lines  Bria-IMT™ is derived from a grade II (moderately differentiated) breast cancer.  Genes expressed by Bria-IMT™ match best with grade I/II-derived Breast Cancer Cell Lines  ~40% of recurrent breast cancers are g

  12. Slide 12: Introducing… Bria-OTS

    Introducing… Bria-OTS™ Bria-OTS™: Off-The-Shelf Personalized Immunotherapy Confirmation of “Matching Hypothesis” resulted in BriaCell’s “OTS” strategy • Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes of Health • We believe BriaCell’

  13. Slide 13: Key Clinical Programs: Development Timeline

    Key Clinical Programs: Development Timeline Anticipated Milestones 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Bria-IMT™ + Incyte Compounds – Pre-Registration Study Data Bria-OTS™ – Authorization by FDA; 1st Patient Dosed Bria-OTS™ – Pre-Registration Study Data Registration Study – Bria-IMT™

  14. Slide 14: Capitalization

    Capitalization Insider Ownership* Outstanding Securities Jamieson Bondarenko 119,856 15.5% Common Shares 771,960 Dr. William Williams 66,886 8.7% Warrants (WAEP $33.45) 266,396 Dr. Charles Wiseman 44,604 5.8% Options (WAEP $46.09) 18,052 Other 10,333 1.3% * Based on 771,960 common shares outstanding

  15. Slide 15: Thank you

    BriaCell Therapeutics Corp. info@BriaCell.com BriaCell.com 1-888-485-6340 Thank you 17

BriaCell Therapeutics — Investor Presentation (February 2021) on 6ix